How severe is CVE-2023-31923?

CVE-2023-31923 has a CVSS 3.x base score of 8.8, rated high severity. It is exploitable over network with low attack complexity, requires low privileges and no user interaction. Impact on confidentiality is high, integrity high, and availability high.

Is CVE-2023-31923 being actively exploited?

It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (54th percentile), an estimate of the probability of exploitation in the next 30 days.

What products are affected by CVE-2023-31923?

CVE-2023-31923 affects Supremainc Biostar 2. See the affected-products list for the exact vulnerable versions.

How do I fix CVE-2023-31923?

Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.

When was CVE-2023-31923 published?

CVE-2023-31923 was published on 2023-05-22 and last updated on 2026-06-17.

CVE-2023-31923

CVE-2023-31923 is a high-severity vulnerability in Supremainc Biostar 2 with a CVSS 3.x base score of 8.8. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-281.

Key facts

Severity: High (CVSS 3.x base score 8.8)
EPSS exploit prediction: 1% (54th percentile)
Actively exploited: Not listed in CISA KEV
Weakness: CWE-281
Affected product: Supremainc Biostar 2
Published: 2023-05-22
Last modified: 2026-06-17

Description

Suprema BioStar 2 before 2022 Q4, v2.9.1 has Insecure Permissions. A vulnerability in the web application allows an authenticated attacker with "User Operator" privileges to create a highly privileged user account. The vulnerability is caused by missing server-side validation, which can be exploited to gain full administrator privileges on the system.

Frequently asked questions

What is CVE-2023-31923?: Suprema BioStar 2 before 2022 Q4, v2.9.1 has Insecure Permissions. A vulnerability in the web application allows an authenticated attacker with "User Operator" privileges to create a highly privileged user account. The vulnerability is caused by missing server-side validation, which can be exploited to gain full administrator privileges on the system.
How severe is CVE-2023-31923?: CVE-2023-31923 has a CVSS 3.x base score of 8.8, rated high severity. It is exploitable over network with low attack complexity, requires low privileges and no user interaction. Impact on confidentiality is high, integrity high, and availability high.
Is CVE-2023-31923 being actively exploited?: It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (54th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2023-31923?: CVE-2023-31923 affects Supremainc Biostar 2. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2023-31923?: Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2023-31923 published?: CVE-2023-31923 was published on 2023-05-22 and last updated on 2026-06-17.

References

https://nobugescapes.com/blog/creating-a-new-user-with-admin-privilege/

Affected products (1)

cpe:2.3:a:supremainc:biostar_2:*:*:*:*:*:*:*:*

More vulnerabilities in Supremainc Biostar 2

CVE-2023-33366 — High (CVSS 8.8): A SQL injection vulnerability exists in Suprema BioStar 2 before 2.9.1, which allows authenticated users to inject…
CVE-2023-33364 — High (CVSS 8.8): An OS Command injection vulnerability exists in Suprema BioStar 2 before V2.9.1, which allows authenticated users to…
CVE-2022-38351 — High (CVSS 8.8): A vulnerability in Suprema BioStar (aka Bio Star) 2 v2.8.16 allows attackers to escalate privileges to System…
CVE-2023-33365 — High (CVSS 7.5): A path traversal vulnerability exists in Suprema BioStar 2 before 2.9.1, which allows unauthenticated attackers to…
CVE-2023-33363 — High (CVSS 7.5): An authentication bypass vulnerability exists in Suprema BioStar 2 before 2.9.1, which allows unauthenticated users to…
CVE-2020-15050 — High (CVSS 7.5): An issue was discovered in the Video Extension in Suprema BioStar 2 before 2.8.2. Remote attackers can read arbitrary…

All CVEs affecting Supremainc Biostar 2 →

Other CWE-281 (Improper Preservation of Permissions) vulnerabilities

CVE-2024-36532 — Critical (CVSS 10.0): Insecure permissions in kruise v1.6.2 allows attackers to access sensitive data and escalate privileges by obtaining…
CVE-2024-56973 — Critical (CVSS 9.8): Insecure Permissions vulnerability in Alvaria, Inc Unified IP Unified Director before v.7.2SP2 allows a remote attacker…
CVE-2024-46622 — Critical (CVSS 9.8): An Escalation of Privilege security vulnerability was found in SecureAge Security Suite software 7.0.x before 7.0.38,…
CVE-2024-55507 — Critical (CVSS 9.8): An issue in CodeAstro Complaint Management System v.1.0 allows a remote attacker to escalate privileges via the…
CVE-2024-54465 — Critical (CVSS 9.8): A logic issue was addressed with improved state management. This issue is fixed in macOS Sequoia 15.2. An app may be…
CVE-2024-41650 — Critical (CVSS 9.8): Insecure Permissions vulnerability in Open Robotics Robotic Operating System 2 ROS2 navigation2 v.humble allows an…

Browse all CWE-281 (Improper Preservation of Permissions) vulnerabilities →